<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538174</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-025</org_study_id>
    <nct_id>NCT00538174</nct_id>
  </id_info>
  <brief_title>Phase I Multiple-Ascending Dose (Japan)</brief_title>
  <acronym>MAD</acronym>
  <official_title>A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and
      pharmacodynamics (PD) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin
      in diabetic Japanese subjects administered for 14 days
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs, vital signs &amp; physical exam</measure>
    <time_frame>scr, Days -3, -1, 1, 2, 7, 12, 13, 14, 15, 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGs</measure>
    <time_frame>scr, Days -1, 1, 2, 7, 12, 13, 14, 15, 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical labs</measure>
    <time_frame>scr, Days -1, 2, 7, 12, 14, 15, 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine safety markers</measure>
    <time_frame>Days -1, 1, 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hr PK blood &amp; urine samples</measure>
    <time_frame>Days 1 &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose, serum insulin, serum c-peptide</measure>
    <time_frame>Days -1, 1, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum fructosamine</measure>
    <time_frame>Days -1, 14, 4 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT</measure>
    <time_frame>Days -2, 13 (after 10 h fast)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h urine</measure>
    <time_frame>Days -1, 1 &amp; 14 for glucose, creatinine &amp; calcium</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets, Oral, once daily up, to 14 days</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, once daily, up to 14 days</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male and female subjects

          -  Ages 20 to 70 years old

          -  Established diagnosis of T2DM

          -  BMI &lt; 32 kg/m2

          -  Fasting glucose â‰¤ 240 mg/dL, while on antidiabetic diet alone

          -  HbA1C 6.0 - 10.0%

        Exclusion Criteria:

          -  Symptomatic T2DM defined as polyuria and/or polydipsia within 2 months of enrollment

          -  History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome

          -  History of incontinence or bladder dysfunction including nocturia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5650853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <results_reference>
    <citation>Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x.</citation>
    <PMID>21226818</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

